Cleavage of ADAMTS-18 by thrombin represents a new mechanism of platelet thrombus clearance via the release of active ~45-kDa C-terminal fragments that induces oxidative platelet fragmentation. The exact cleavage sites remain unclear, but Arg (R) 775 /Ser (S) 776 in spacer region of ADAMTS-18 has been shown to be one of the cleavage sites of thrombin. Here, we demonstrate that R 792 /S 793 and R 823 /S 824 are also thrombin cleavage sites by sequence analysis, amino acid mutation and mass spectrometry assay. All these cleavage sites are thrombin-specific and insensitive to other enzymes tested (e.g. cathepsin D or trypsin). Simultaneous mutation of R 775 , 792 , 823 to S 775 , 792 , 823 in ADAMTS-18 completely abrogated the cleavage by thrombin and the generation of active C-terminal 45-kDa fragments. Together with previous study, a total of three thrombin-specific cleavage sites have been identified in spacer region of ADAMTS-18.
Introduction
ADAMTS (a disintegrin and metalloproteinase domain, with thrombo spondin type-1 modules) is a family of 19 secreted Zn-metalloproteinases, which have multidomain structural components in common [1] . These include an N-terminal signal peptide, followed by a pro-domain, a metalloproteinase catalytic domain with a zinc binding motif, a disintegrin-like domain, a central thrombospondin type-1-like repeat (TSR), a cysteine rich domain (high sequence homology), a spacer region, and a variable number of C terminal TSR repeats. This family plays important roles in several pathophysiological conditions mainly including arthritis [2] , spermatogenesis [3] , angiogenesis [4] [5] , and thrombosis-related disease [6] . Noteworthily, most of these activities are related to proteolytic processing within their C-terminal regions [6] - [9] .
ADAMTS-18 has the similar domain organization as other family members. ADAMTS-18 has been shown to be epigenetically silenced in multiple carcinomas and has tumor suppressor activity [10] . Mutation of ADAMTS-18 is strongly associated with colorectal cancer [11] . The data from National Center for Biotechnology Information (NCBI) subject's gene expression omnibus (GEO) also showed that ADAMTS-18 gene was differentially expressed in subjects with normal skeletal fracture versus subjects with nonunion skeletal fracture [12] . Therefore, it is also associated with bone mineral density (BMD) determination in the major human ethnic groups. Recently, some studies indicate that the ADAMTS-18 gene is also play a crucial role in early eye development [13] .
Platelet integrin αIIbβ3 (GPIIb/IIIa) is a heterodimeric receptor of the integrin family expressed at high density (50,000 -80,000 copies/cell) on the platelet plasma membrane [14] . GPIIIa49-66 (CAPESIEFPVSEAREVLED) is a linear epitope of integrin subunit β3 (GPIIIa) in its extracellular domain. We previously reported that the unique feature of the antibodies (Abs) against GPIIIa49-66 was their ability to induce reactive oxygen species (ROS) through the activation of 12-lipoxygenase and nicotinamide adenine dinucleotide phosphate oxidase (NADPH), leading to complement-independent platelet fragmentation [15] [16] . Recently, we revealed that ADAMTS-18 was the physiologic ligand of platelet GPIIIa49-66 [17] . Thrombin generated from the endothelium of vessel injury is able to cleave ADAMTS-18. The generated ~45-kDa C-terminal cleavage product of ADAMTS-18 becomes activated. It clusters the β3 integrins and induces oxidative platelet fragmentation as we previously described anti-GPIIIa 49 -66 Ab [17] . We have identified that R 775 /S 776 in spacer region of ADAMTS-18 is one of the potential cleavage sites of thrombin [18] , which also generate similar ~45-kDa C-terminal products in theory when cleaved by thrombin. In this study, we have investigated other thrombin cleavage sites in spacer region of ADAMTS-18 through amino acid mutation and mass spectrometry assay.
Materials and Methods

Reagents
All reagents were obtained from Sigma (St. Louis, MO) unless otherwise designated. Full-length ADAMTS-18 cDNA coding sequence was purchased from ATCC and cloned into mammalian expression vector pBudCE4.1 from Invitrogen (Carlsbad, CA) [17] [18] . ADAMTS-18 peptides were synthesized by Sangon Biotech (Shanghai, China). The in vitro Transcend™ Biotinylated Translation Detection Systems was purchase from Promega (Madison, WI, USA).
In Vitro DNA Translation and Thrombin Cleavage Assay
Biotinylated-methionine-labeled ADAMTS-18 or its mutant was translated using an in vitro Transcend™ Biotinylated Translation Detection Systems following the protocol provided by the manufacturer. All the peptides or translated proteins were then digested by thrombin or cathepsin D or trypsin according to the protocol provided by the manufacture.
Immunoblotting
In vitro translation products were separated by 12% SDS/PAGE gels, transferred to a nitrocellulose membrane, and immunoblotted with horseradish peroxide (HRP) conjugated avidin for 1 hour followed by washing with PBST (0.1% Tween 20). The signal band was detected by chemiluminescence substrate [18] .
Mass Spectrometry
Mass spectrometry was performed as previously described [18] . Briefly, for analysis of ADAMTS-18 cleavage products, a fresh mixture of enzyme and ADAMTS-18 peptide was submitted to molecular weight determination by Matrix assisted laser desorption ionization quadrupole time of flight (MALDI-QTOF) mass spectrometry (MS) (Applied Biosystems 4700 Proteomics Analyzer). To determine the amino acid sequences of newly observed peaks, MS/MS peptide de novo sequencing using a specific software program (Applied Biosystems DeNovo Explorer) was performed.
Results
Thrombin Cleavage of C-Terminal ADAMTS-18 on Several Sites
Previous study has shown that the full-length ADAMTS-18 is proteolyzed by thrombin and results in ~45-kDa C-terminal fragments releasing [17] . The optimal cleavage site for thrombin is R/X [X refers to nonacidic amino acid mainly including R, lys (K), His (H), and Ser (S)] (Figure 1(a) (Figure 1(b) ). The possible molecular weight from these predicted sites to C terminal is ~49-, 47-and 43-kDa, respectively (Figure 1(c) ). Therefore, it remained uncertain whether R 792 /S 793 and R 823 /S 824 were also the actual sites of proteolysis.
Susceptibility of Thrombin for R 792 /S 793 and R 823 /S 824 of C-Terminal ADAMTS-18
To explore these predictions, we synthesized peptides covering the other two putative cleavage sites. The P06594 is ~3134.5 Da when incubated with PBS buffer (Figure 2(a) ). However, thrombin cleaved 27-mer P06594 at R/S site, producing 15-mer N terminal peptide PGEFPFAGTTFEYQR (~1746.6 Da) and 12-mer C terminal peptide SFNRPERLYAPG (~1406.6 Da), respectively (Figure 2(b) ). The generation of 15-mer peptide becomes obvious when the concentration of thrombin beyond 5 U/ml (Figure 2(c) ). Consistently both PBS and thrombin had no effect on P06595 (PGEFPFAGTTFEYQSSFNRPERLYAPG), in which R 823 was mutated to S 823 (Figure 2(d) and Figure 2(e) ). The generation of 15-mer peptide completely abrogated when cleaved by various concentrations of thrombin (Figure 2(f) ). Hirudin completely inhibited the generation of MW1746.6 and MW1406.6 peak suggesting the specificity of thrombin cleavage (Figure 3 Table 1) . We also incubated these peptides with other enzyme cathepsin D or trypsin, and assayed by mass spectrometry. It demonstrated that these cleavage sites are thrombin-specific, and insensitive to cathepsin D or trypsin ( Table 1 ).
Specificity of Thrombin for Site-Mutated ADAMTS-18 Full-Length Protein
Since R/S 775 , 792 and 823 in spacer region of ADAMTS-18 are critical for thrombin cleavage, we further constructed mammalian expression vector in which all these susceptible sites were mutated to S/S-775 , 792 and 823 (Figure 4(a) ). (Figure 4(b) ). The expression of ~75 kDa short form of ADAMTS-18 is consistent with our previous report [18] . Figure 4 (c) demonstrates wide type ADAMTS-18 is proteolyzed by thrombin, and the cleavage fragment is about ~45-kDa. However, thrombin had no effect on mutated ADAMTS-18 in various concentrations (Figure 4(d) ). 
Discussion
Despite the similarity shared by ADAMTS family members, most differences among them are found in the Cterminal domains of the protein, suggesting that the C-terminal domains of ADAMTS may determine their in vivo location and substrate specificity [19] - [22] . C-terminal processing has been shown in ADAMTS-1 [19] [21], ADAMTS-4 [20] [22], ADAMTS-8 [4] , ADAMTS-9 [5] , and ADAMTS-13 [6] . This splicing will shed light on the biological function of these important proteins. Noteworthily, most of cleavage events occur within the spacer region [19] - [22] .
We previously reported that cleavage of ADAMTS-18 by thrombin represent a novel mechanism for platelet thrombus clearance [17] . The release of the active 45-kDa C-terminal fragment could regulate thrombus size by inducing oxidative platelet fragmentation. In this study, we first revealed that the R 775 /S 776 , R 792 /S 793 and R 823 /S 824 in spacer region of ADAMTS-18 are critical for thrombin cleavage. This cleavage region is similar to those of the ADAMTS family members reported previously [19] - [22] . Physiologically, thrombin is generated rapidly, and at high local concentrations during the normal hemostatic response. We found that ADAMTS-18 was proteolyzed by thrombin at a high thrombin concentration, whereas low thrombin concentration had undetectable cleavage effect on ADAMTS-18 which mimics some physiological conditions, especially platelet thrombus formation. It is of interest in this regard that ADAMTS-13 has recently been shown to be inactivated by thrombin contributing to the loss of ADAMTS-13 VWF cleavage function [6] . Furthermore, ADAMTS-13 has been reported to limit platelet thrombus formation in a shear rate dependent platelet thrombus model on collagen, by its cleavage of ultra large VWF [23] .
In present study, we also find ~75-kDa band which is from ADAMTS-18 cDNA in in vitro translation assays. Thrombin or other enzyme (cathepsin D or trypsin) had no effect on the generation of this band. Thus, it is likely other mechanism has been involved in the ADAMTS-18 processing.
Conclusion
In summary, this report provides a direct proof that the existence of C-terminal proteolytic cleavage sites of ADAMTS-18 by thrombin, has potential drug application in dissolution of arterial thrombi.
